Table 4. Data on children and adolescents with aneurysmal bone cyst treated with denosumab reported in the literature.

Study	Year	Patient’s age	Dose and interval of denosumab	Duration of treatment	Effect of treatment	Adverse events during treatment	Adverse events after treatment
Lange et al. (21)	2013	8- and 11-year-old boys	70 mg/m2 monthly	Ongoing	Cyst partial regression, improved pain	Mild hypocalcemia (1 patient)	Unknown
Pelle et al. (22)	2014	5-year-old boy	1.2–1.6 mg/kg monthly	12 months	Cyst regression, healed fracture, improved pain	None	Unknown
Fontenot et al. (23)	2018	13-year-old girl	Subcutaneous denosumab (120 mg) given every 4 weeks (with additional 120 mg SC doses on days 8 and 15 in cycle 1 only)	12 months	Pain improved, decreased tumor size	None	None
Raux et al. (24)	2019	Median age was 8 years (range, 7–17 years)	70 mg/m2	A median of 12 months (range, 4–23 months)	Free of pain, and the neurological deficits in 3 patients had improve	Hypocalcemia	Hypercalcemia
Harcus et al. (25)	2020	1 child, 13 years old	Subcutaneous denosumab (70 mg/m2) on a weekly–2 months–3 months–4 months–6 months		Pain free, new bone formation in the lesion	Calcification of the lower limb growth plates	Rebound hypercalcemia
Fadavi et al. (26)	2021	1 child, 13 years old	120 mg every 4 weeks	12 months	Neurologic symptoms fully recovered	None	None